Dialyse aktuell 2010; 14(3): 170-172
DOI: 10.1055/s-0030-1253290
Forum der Industrie

© Georg Thieme Verlag KG Stuttgart ˙ New York

Therapie von chronisch Nierenkranken ‐ Welche Rolle spielt die selektive VDR-Aktivierung?

Further Information

Publication History

Publication Date:
06 April 2010 (online)

Also available at
 

Ende November hielt Prof. Kamyar Kalantar-Zadeh, Los Angeles (USA), bei der Herbsttagung des Colloquiums nephrologicum Thüringen einen Vortrag über selektive VDR-Aktivierung (sVDRA), der auf viel Interesse stieß und lebhaft diskutiert wurde. Denn mit fortschreitender chronischer Nierenerkrankung (CKD) sind Hyperphosphatämie, Hypokalzämie und Mangel an 1,25-Vitamin-D3 die Hauptfaktoren für die Entwicklung des sekundären Hyperparathyreoidismus (sHPT). Kalantar-Zadeh gab einen ganz aktuellen Überblick über den Wissensstand zum Thema sHPT und zur Bedeutung der selektiven VDR-Aktivierung in der Therapie von CKD-Patienten.

Literatur

  • 01 Kovesdy C P, Ahmadzadeh S , Anderson J E, Kalantar-Zadeh K . Association of activated vitamin D treatment and mortality in chronic kidney disease.  Arch Intern Med. 2008;  168 397-403
    Search in Google Scholar
  • 02 Shinaberger C S, Kopple J D, Kovesdy C P, et al . Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients.  Clin J Am Soc Nephrol. 2008;  3 1769-1776
    Search in Google Scholar
  • 03 Regidor D L, Kovesdy C P, Mehrotra R , et al . Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients.  J Am Soc Nephrol. 2008;  19 2193-2203
    Search in Google Scholar
  • 04 Shantouf F , Kovesdy C P, Kim Y , et al . Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients.  Clin J Am Soc Nephrol. 2009;  4 1106-1114
    Search in Google Scholar
  • 05 Kalantar-Zadeh K , Kovesdy C P. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease.  Clin J Am Soc Nephrol. 2009;  4 1529-1539
    Search in Google Scholar
  • 06 Dukkipati R , Kalantar-Zadeh K , Kopple J D. Is there a role for intradialytic parenteral nutrition? A review of the evidence.  Am J Kidney Dis. 2010;  55 352-364
    Search in Google Scholar
  • 07 Teng M , Wolf M , Lowrie E , et al . Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.  N Eng J Med. 2003;  349 446-456
    Search in Google Scholar
  • 08 Teng M , Wolf M , Ofshun M N, et al . Activated injectable vitamin D and hemodialysis survival: a historical cohort study.  J Am Soc Nephrol. 2005;  16 1115-1125
    Search in Google Scholar
  • 09 Lund R J, Andress D L, Amdahl M , et al . Absorption in Hemodialysis Patients.  Am J Nephrol. 2010;  31 165-170
    Search in Google Scholar
  • 10 Mizobuchi M , Finch J L, Martin D R, et al . Differential effects of vitamin D receptor activators on vascular calcification in uremic rats.  Kidney Int. 2007;  72 709-715
    CrossrefSearch in Google Scholar
  • 11 Wu-Wong J R, Noonan W , Ma J , et al . Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification.  J Pharmacol Exp Ther. 2006;  318 90-98
    CrossrefSearch in Google Scholar
  • 12 Henley C , Colloton M , Cattley R C, et al . 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.  Nephrol Dial Transplant. 2005;  20 1370-1377
    CrossrefSearch in Google Scholar
  • 13 Agarwal R , Acharya M , Tian J , et al . Antiproteinuric effect of oral paricalcitol in chronic kidney disease.  Kidney Int. 2005;  68 2823-2828
    CrossrefSearch in Google Scholar
  • 14 Alborzi P , Patel N A, Peterson C , et al . Paricalcitol reduces albuminuria and inflammation in chronic kidney disease. A randomized double-blind pilot trial.  Hypertension. 2008;  52 249-255
    Search in Google Scholar
  • 15 de Zeeuw D , Agarwal R , Parving H , et al . A study of paricalcitol capsules on reducing albuminuria in type 2 diabetic nephropathy being treated with renin-angiotensin system inhibitors (NCT00421733). Im Internet:. http://www.clinicaltrials.gov 08.03.2010

01 Selective Vitamin D Receptor (VDR) Activator for Albuminuria Lowering (VITAL) Study in Type 2 Diabetic Nephropathy